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Glecaprevir and Pibrentasvir for 12
Weeks for Hepatitis C Virus Genotype 1
Infection and Prior Direct-Acting
Antiviral Treatment
Fred Poordad,1 Franco Felizarta,2 Armen Asatryan,3 Mark S. Sulkowski,4 Robert W. Reindollar,5 Charles S. Landis,6
Stuart C. Gordon,7 Steven L. Flamm,8 Michael W. Fried,9 David E. Bernstein,10 Chih-Wei Lin,3 Ran Liu,3 Sandra S. Lovell,3
Teresa I. Ng,3 Jens Kort,3 and Federico J. Mensa3
Although direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high
rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resis-
tance, which can decrease the effectiveness of subsequent treatment. Treatment options for patients who failed previous
DAA-containing regimens, particularly those with nonstructural protein 5A inhibitors, are limited and remain an area of
unmet medical need. This phase 2, open-label study (MAGELLAN-1) evaluated the efﬁcacy and safety of glecaprevir
(GLE) 1 pibrentasvir (PIB) 6 ribavirin (RBV) in HCV genotype 1–infected patients with prior virologic failure to HCV
DAA-containing therapy. A total of 50 patients without cirrhosis were randomized to three arms: 200 mg GLE 1 80 mg
PIB (arm A), 300 mg GLE 1 120 mg PIB with 800 mg once-daily RBV (arm B), or 300 mg GLE 1 120 mg PIB with-
out RBV (arm C). By intent-to-treat analysis, sustained virologic response at posttreatment week 12 was achieved in
100% (6/6, 95% conﬁdence interval 61-100), 95% (21/22, 95% conﬁdence interval 78-99), and 86% (19/22, 95% conﬁ-
dence interval 67-95) of patients in arms A, B, and C, respectively. Virologic failure occurred in no patients in arm A and
in 1 patient each in arms B and C (two patients were lost to follow-up in arm C). The majority of adverse events were
mild in severity; no serious adverse events related to study drug and no relevant laboratory abnormalities in alanine amino-
transferase, total bilirubin, or hemoglobin were observed. Conclusion: The combination of GLE and PIB was highly efﬁca-
cious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; RBV
coadministration did not improve efﬁcacy. (HEPATOLOGY 2017;66:389-397).
Hepatitis C virus (HCV) genotype (GT) 1 isthe most common among HCV GTs glob-ally, accounting for approximately 46% of an
estimated 185 million infections worldwide.(1,2)
Although the treatment landscape for HCV has rapid-
ly evolved with highly effective and safe treatments for
patients with GT1 infection,(3,4) as direct-acting anti-
viral (DAA) agents are used extensively, the number of
patients with virologic failure of DAA regimens contin-
ues to grow.(5) Virologic failure of DAAs often results
from baseline resistance-associated polymorphisms or
resistance-associated substitutions that emerge during
therapy.(4-8) Variants within the HCV nonstructural
protein 5A (NS5A) region substantially increase the
risk of virologic failure for many DAA-containing regi-
mens,(9,10) and there are currently no treatments speciﬁ-
cally indicated for either NS5A or NS5B inhibitor–
experienced patients.
DAA treatment failure is a growing concern given
the long-term persistence of NS5A resistance-
associated variants(11,12) and suboptimal treatment
response rates in patients with resistance-associated
Abbreviations: CI, conﬁdence interval; DAA, direct-acting antiviral; EC50, half-maximal effective concentration; GLE, glecaprevir; GT, genotype;
HCV, hepatitis C virus; ITT, intent-to-treat; mITT, modiﬁed ITT; NS, nonstructural; PI, protease inhibitor; PIB, pibrentasvir; RBV, ribavirin;
SVR12, sustained virologic response at posttreatment week 12.
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baseline polymorphisms or treatment-emergent substi-
tutions.(9,13,14) Retreatment strategies using 24 weeks
of ledipasvir/sofosbuvir have demonstrated a 60% sus-
tained virologic response at posttreatment week 12
(SVR12) rate among patients with baseline NS5A poly-
morphisms and 33% in patients with NS5A Y93H/N
polymorphisms.(14) Similarly, the combination regimen
of elbasvir and grazoprevir has reduced efﬁcacy (70%) in
GT1a-infected patients with baseline NS5A resistance-
associated polymorphisms at elbasvir-speciﬁc positions
(e.g., M28, Q30, L31, Y93).(9,15) In addition, the com-
bination of sofosbuvir/velpatasvir has reduced potency
to HCV GT1a NS5A variants at position Y93, includ-
ing the common Y93H variant, which confers a 609-
fold increase in half-maximal effective concentration
(EC50) to velpatasvir.(16) Therefore, treatments with a
high barrier to viral resistance that maintain potency
against viral variants, particularly for patients previously
treated with HCV DAAs, are needed.
Current recommended retreatment strategies for
patients with prior failure of NS3/4A protease inhibitor
(PI)–containing DAA regimens include the NS5B
nucleotide analogue inhibitor sofosbuvir plus an NS5A
inhibitor (ledipasvir, velpatasvir, or daclatasvir) for 12
weeks or the combination of the NS3/4A PI grazoprevir
plus the NS5A inhibitor elbasvir with ribavirin (RBV)
for 16 weeks.(16) Patients with baseline NS5A variants,
either preexisting or the result of treatment emergence
from prior exposure to an NS5A inhibitor, have proven
more difﬁcult to cure with approved DAA regimens;
thus, longer treatment durations, addition of RBV, and
the addition of a third or fourth DAA have been exam-
ined to maximize SVR12 rates.(14,17-20)
Glecaprevir (GLE; formerly ABT-493; identiﬁed
by AbbVie and Enanta) is an HCV NS3/4A PI that
has potent pangenotypic antiviral activity. GLE does
not inhibit human proteases, exhibits in vitro EC50
values 5 nanomolar across all major HCV GTs, and
demonstrates <5-fold loss of activity against common
GT1 variants at key resistance-associated positions of
R155 and D168 to currently available NS3/4A
PIs.(6,21) Pibrentasvir (PIB; formerly ABT-530) is an
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HCV NS5A inhibitor with EC50 values 5 picomolar
across all major HCV GTs; it maintains high potency
against common NS5A resistance-associated variants,
including GT1a Y93H (6.7-fold increase in
EC50),(22) which has been associated with reduced
susceptibility to other NS5A inhibitors, such as ledi-
pasvir (3,294-fold increase in EC50), daclatasvir
(1,600-fold increase in EC50), and velpatasvir (609-
fold increase in EC50).(23)
In part 1 of the MAGELLAN-1 study, we evaluat-
ed the efﬁcacy and safety of GLE 1 PIB for 12 weeks,
with or without RBV, in patients with prior treatment
failure of HCV regimens containing an NS5A inhibi-
tor and/or NS3/4A PI with or without NS5B inhibi-
tors. The impacts of baseline polymorphisms and RBV
coadministration on SVR12 rates were also assessed.
Materials and Methods
STUDY OVERVIEW AND
REGIMENS
The MAGELLAN-1 (NCT02446717) study was a
phase 2, randomized, open-label, multicenter study that
assessed the efﬁcacy and safety of GLE 1 PIB in HCV
GT1-infected patients with prior DAA treatment expe-
rience. Patients were initially randomized 1:1:1 into three
arms (A, B, and C; Fig. 1). Patients enrolled in arm A
were treated for 12 weeks with GLE (200 mg once daily)
1 PIB (80 mg once daily); however, a protocol amend-
ment was implemented to halt enrollment (with 6
patients enrolled) to optimize doses of GLE and PIB for
further development.(24) Subsequent to this protocol
amendment, the remaining enrolled patients were ran-
domized 1:1 into arm B or C for treatment with GLE
(300 mg once daily) 1 PIB (120 mg once daily) with
RBV (arm B; 800 mg once daily) or without RBV (arm
C) for 12 weeks. Patients were stratiﬁed by HCV sub-
type (1b or non-1b) and previous DAA class (NS5A
inhibitor-experienced, NS3/4A PI-experienced but
NS5A inhibitor-naive, or other). For the purpose of
analysis, previous HCV treatment experience was
deemed cumulative (i.e., a patient exposed to NS3/4A PI
and subsequently to NS5A inhibitor was considered
NS5A and NS3/4A PI-experienced). All patients signed
informed consent, and the study was conducted in accor-
dance with its protocol (designed and sponsored by Abb-
Vie), the Good Clinical Practice Guidelines, and the
ethical principles set forth in the Declaration of Helsinki,
with independent ethics committee or institutional
review board approval for all study sites.
PATIENT POPULATION,
CRITERIA, AND STUDY DESIGN
Patients were adults, 18-70 years, without cirrhosis
but with chronic HCV GT1 infection and treatment-
experienced with a prior DAA-containing regimen.
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FIG. 1. MAGELLAN-1, part 1, clinical trial design schematic. In part 1 of the MAGELLAN-1 study, patients were randomized
1:1:1 into three treatment arms, stratiﬁed by HCV subtype (1b or non-1b) and previous DAA classiﬁcation (NS5A inhibitor–experi-
enced, NS3/4A PI–experienced but NS5A inhibitor-naive, or other). Enrollment in arm A was halted by protocol amendment after 6
patients were randomized to that arm (see Materials and Methods). In total, 50 patients were enrolled to receive GLE 1 PIB 6
RBV, once daily, for 12 weeks. The primary endpoint was the proportion of patients with SVR12.
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Patients had to have completed past DAA treatment at
least 1 month prior to screening visit, with the outcome
of prior HCV treatment being either on-treatment viro-
logic failure or posttreatment relapse. Plasma samples
for HCV genotyping were collected at screening and
assessed with the Versant HCV Genotype Inno LiPA
Assay, version 2.0 or higher. The absence of cirrhosis
(METAVIR score 3, Ishak score 4) was determined
by one of the following: liver biopsy within 24 months
prior to (or during) screening, transient elastography
(FibroScan) result of <12.5 kPa within 6 months prior
to (or during) screening, or a screening FibroTest score
of 0.48 with an aspartate aminotransferase to platelet
ratio index <1. Patients coinfected with hepatitis B
virus, human immunodeﬁciency virus, or more than one
HCV GT at screening were excluded. Key eligibility
criteria and deﬁnitions of prior treatment responses are
provided in the Supporting Information.
EFFICACY, VIROLOGIC, AND
SAFETY ASSESSMENTS
Plasma samples for HCV RNA measurements were
collected at screening; treatment days 1 and 3 and weeks
1, 2, 4, 6, 8, 10, and 12 (or early discontinuation); and
posttreatment weeks 2, 4, 8, 12, and 24 (or early discon-
tinuation) and assessed using the COBAS AmpliPrep/
COBAS TaqMan HCV Quantitative Test, version 2.0.
The primary efﬁcacy endpoint was the percentage of
patients who achieved SVR12 (HCV RNA <15 IU/
mL) in the intent-to-treat (ITT) population, deﬁned as
all randomized patients who received at least one dose
of study drug. A modiﬁed ITT (mITT) analysis was
also conducted, excluding all nonvirologic failures (i.e.,
patients lost to follow-up or early discontinuation).
Two-sided conﬁdence intervals (CIs) were determined
at a signiﬁcance level of 0.05 using the Wilson score
method for binomial proportions. Statistical summaries
were performed using SAS software, version 9.3.
Viral sequences from the baseline plasma sample for
each patient were analyzed by next-generation sequencing
(Illumina MiSeq) to identify NS3 or NS5A polymor-
phisms at detection thresholds of 2% and 15%. For
patients who had virologic failure within the study, the
ﬁrst samples with HCV RNA 1,000 IU/mL collected
at or after the time of virologic failure were also analyzed
by next-generation sequencing at the same thresholds.
Sequences were compared to the corresponding baseline
and reference sequences to identify amino acid substitu-
tions that could be associated with resistance to compo-
nents of the therapy. For HCV resistance analysis, a
polymorphism was deﬁned as a baseline amino acid dif-
ference relative to the appropriate subtype-speciﬁc refer-
ence sequence; despite DAA-experienced patients having
had prior HCV antiviral therapy, a patient’s baseline ami-
no acid variants in this study were considered polymor-
phisms as the patient’s HCV amino acid sequences prior
to all previous therapies are unknown. A substitution was
deﬁned as a treatment-emergent amino acid sequence dif-
ferent from the patient’s baseline viral sequence. An ami-
no acid variant was considered an amino acid change due
to a baseline polymorphism or treatment-emergent sub-
stitution. Detailed information on the collection of plas-
ma samples, HCV RNA measurement, virologic-failure
criteria, and amino acid variants included in resistance
analysis are available in the Supporting Information.
Safety assessments were based on the safety popula-
tion (same as the ITT population). Safety and tolera-
bility assessments were conducted at screening and
throughout the study and included monitoring vital
signs, physical examinations, adverse events, and clini-
cal chemistry and hematology tests. Adverse events
were recorded up to 30 days posttreatment.
Results
A total of 91 patients with HCV GT1 were
screened in the United States; 50 were randomized
and received at least one dose of study drug. Patients
not randomized due to abnormal laboratory values had
elevated alanine aminotransferase, aspartate amino-
transferase, direct bilirubin, or low platelet count.
Among randomized patients, 82% were male, 34%
reported black race, and 84% had GT1a infection
(Table 1). The majority of patients (66%) had prior
treatment failure of regimens containing multiple
DAAs; 50% had been previously treated with an
NS5A inhibitor, 84% with an NS3/4A PI, and 54%
with an NS5B polymerase inhibitor. Of 27 patients
with NS5B polymerase inhibitor exposure, 56% had
prior treatment with a nucleotide analogue inhibitor,
33% had treatment with non-nucleoside inhibitors,
and 11% had exposure to both. The most common pri-
or DAA-containing regimens were boceprevir plus
pegylated interferon/RBV (n 5 10), telaprevir plus
pegylated interferon/RBV (n 5 8), ledipasvir/sofosbu-
vir (n 5 8), and simeprevir plus sofosbuvir with or
without RBV (n 5 8) (Supporting Table S1). Overall,
21/50 patients had prior failure to NS3/4A PI 1 pegy-
lated interferon/RBV; 5 of those 21 patients were also
experienced with NS5A or NS5B inhibitors within the
POORDAD ET AL. HEPATOLOGY, August 2017
392
interferon-containing regimen or within other regi-
mens. The type of prior DAA experience (NS3/4A PI
only or NS5A inhibitor only or both) was well bal-
anced across treatment groups (Table 1). Next-
generation sequencing identiﬁed baseline polymor-
phisms in NS3 and/or NS5A in 86% (43/50) of
patients at a detection threshold of 2% and in 80%
(40/50) of patients at a threshold of 15%. At a 15%
detection threshold, the majority of patients had at
least one baseline polymorphism across all treatment
groups; although no patients in arm A had polymor-
phisms in both NS3 and NS5A targets, 27%(6/22)
and 41% (9/22) had polymorphisms in both targets in
arms B and C, respectively (Table 1). In addition,
baseline NS5A polymorphisms were detected in 50%
(3/6), 50% (11/22), and 55% (12/22) of patients in
arms A, B, and C, respectively, at a detection threshold
of 15%. Although a detection threshold of 15% is
commonly accepted as clinically relevant, lower thresh-
olds of detection give greater insight into amino acid
changes that may emerge in the majority of the popu-
lation after prior therapy with DAA-containing regi-
mens. At a more sensitive 2% detection threshold, the
most common polymorphisms in NS3 were at amino
acid positions Q80 (n 5 23), R155 (n 5 4), D168
(n5 4), and I/V170 (n5 4); and those for NS5A were
at positions Q30 (n 5 14), Y93 (n 5 8), L31 (n 5 7),
M28 (n 5 6), Q54 (n 5 6), and H/P58 (n 5 5). Base-
line amino acid polymorphisms detected at a threshold
of 2% are shown in Supporting Table S2, and the prev-
alence of speciﬁc polymorphisms detected at both 2%
and 15% is summarized in Supporting Table S3.
Overall, by ITT analysis, SVR12 was achieved in
92% (46/50, 95% CI 81-97) of patients treated with
GLE 1 PIB with or without RBV for 12 weeks. In
the halted arm A, in which patients received the lower
dose of 200 mg GLE and 80 mg PIB, 100% (6/6, 95%
CI 61-100) of patients achieved SVR12. In arm B
(300 mg GLE 1 120 mg PIB 1 800 mg RBV for 12
weeks) SVR12 was achieved in 95% (21/22, 95% CI
78-99) of patients, and among patients in arm C (300
mg GLE 1 120 mg PIB for 12 weeks), 86% (19/22,
95% CI 67-95) of patients achieved SVR12 (Fig. 2).
The rates of virologic failure were identical (1/22, 5%)
with or without administration of RBV (arm B versus
arm C). The two patients in arm C who did not
TABLE 1. Patient Demographics and Baseline Characteristics
Characteristic
Arm A GLE1PIB
(200 mg 1 80 mg)
n 5 6
Arm B GLE1PIB
(300 mg 1 120 mg) 1
RBV (800 mg)
n 5 22
Arm C GLE1PIB
(300 mg 1 120 mg)
n 5 22
Male, n (%) 3 (50) 20 (91) 18 (82)
Black race,* n (%) 2 (33) 5 (23) 10 (45)
Age, median years (range) 59 (39-61) 56 (39-64) 59 (46-70)
HCV subtype, n (%)
1a 4 (67) 20 (91) 18 (82)
1b 2 (33) 2 (9) 4 (18)
Treatment experience by DAA class, n (%)
NS5A-experienced/PI-naive 0 4 (18) 4 (18)
NS5A-naive/PI-experienced 3 (50) 11 (50) 11 (50)
NS5A-experienced/PI-experienced 3 (50) 7 (32) 7 (32)
BMI, median kg/m2 (range) 27 (25-37) 28 (22-34) 28 (19-37)
IL28B non-CC genotype, n (%) 4 (67) 16 (73) 19 (86)
HCV RNA, median log10 IU/mL (range) 6.1 (5.6-6.7) 6.7 (5.0-7.3) 6.6 (5.5-7.2)
HCV RNA 6,000,000 IU/mL, n (%) 0 11 (50) 10 (46)
Baseline fibrosis stage, n (%)
F0-F1 4 (67) 17 (77) 11 (50)
F2 1 (17) 0 6 (27)
F3 1 (17) 5 (23) 5 (23)
Baseline polymorphisms,† n (%)
Any polymorphism (NS3 or NS5A) 5 (83) 18 (82) 17 (77)
NS3 only 2 (33) 7 (32) 5 (23)
NS5A only 3 (50) 5 (23) 3 (14)
Both NS3 and NS5A 0 6 (27) 9 (41)
*Race was self-reported.
†Polymorphisms were detected at a 15% detection threshold with next-generation sequencing. “Only” indicates total number of
patients with baseline polymorphisms within the indicated target and none in the other target.
Abbreviation: IL28B, interleukin 28B.
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achieve SVR12 were lost to follow-up; however, both
patients had undetectable HCV RNA at posttreatment
week 8. By mITT analysis, excluding patients who
failed to achieve SVR12 for nonvirologic reasons,
SVR12 rates were 100%, 95%, and 95% for arms A, B,
and C, respectively.
Two conﬁrmed virologic failures were observed;
both patients were compliant and had on-treatment
drug levels of GLE and PIB that were consistent with
those observed in other patients (Table 2). The patient
in arm C (300 mg GLE 1 120 mg PIB) had on-
treatment HCV breakthrough at week 8; using a 2%
detection threshold, this patient had baseline polymor-
phisms in both NS3 (Y56H and D168A/T) and
NS5A (M28V, Q30R, and H58C). At the time of
virologic failure, this patient had treatment-emergent
substitutions of V36M in NS3 and M28G in NS5A.
Of note, although GLE and PIB levels in this patient
were within expected therapeutic ranges, the patient
had Crohn’s disease, was receiving immunosuppressive
therapy, and had a prior ileocolectomy. The other
patient who had virologic failure was a posttreatment
week 4 relapse in arm B (300 mg GLE 1 120 mg PIB
1 800 mg RBV) and had baseline NS5A polymor-
phisms L31M and H58D, with no polymorphisms in
NS3. At the time of relapse, this patient had
treatment-emergent substitutions of A156V in NS3
and Q30R in NS5A. Overall, in patients with baseline
polymorphisms in NS3 only, NS5A only, or both NS3
and NS5A at a 15% detection threshold, SVR12 rates
were 100% (14/14), 91% (10/11), and 93% (14/15),
respectively; SVR12 was achieved by 100% (10/10) of
patients with no baseline polymorphisms in NS3 or
NS5A.
Adverse events were mostly mild in severity and
reported in 84% of patients. Adverse events occurring
in 10% of patients were headache, fatigue, nausea,
and insomnia (Table 3); such events were more com-
mon in the RBV-containing arm. Two treatment-
emergent serious adverse events were reported, neither
of which was deemed related to study drug by the
investigator (fractured femur and breast cancer). No
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FIG. 2. Sustained virologic response in the ITT and mITT pop-
ulations. Individual SVR12 rates for arm A (blue), arm B (green),
and arm C (gray-blue) are shown for the ITT and mITT popula-
tions. The ITT population was all patients that received at least
one dose of study drug (n 5 50), while the mITT population
excluded all patients who did not achieve SVR for reasons other
than virologic failure. Whiskers represent the 95% CI using the
Wilson score method. Both patients lost to follow-up had nonde-
tectable HCV RNA at posttreatment week 8. Abbreviation:
LTFU, lost-to-follow-up.
                                                                 
TABLE 2. Characteristics of Patients with Virologic Breakthrough or Relapse
Subgenotype
Prior
treatment
12-Week
treatment
Reason for
nonresponse
Time point
sequenced NS3 variants* NS5A variants*
1a DCV; GLE 1 PIB 1 RBV Relapse† Baseline None L31M, H58D (26%)
TVR 1 PR 300 mg 1 120 mg
1 800 mg
PTW4 A156V (91%) Q30R, L31M, H58D
1a OBV 1 PTV/RTV 1
DSV 1RBV
GLE 1 PIB Breakthrough Baseline Y56H (5%), D168A/
T (94%/3%)
M28V (3%), Q30R
(98%), H58C (99%)
300 mg 1 120 mg Week 8 V36M (6%), Y56H,
D168A
M28G, Q30R (99%),
H58C
*Variants due to baseline polymorphisms or treatment-emergent substitutions.
†This patient had Crohn’s disease, was on immunosuppressant therapy, and had prior ileocolectomy.
Variants were detected at a 2% detection threshold with next-generation sequencing. Only variants with prevalence 2% are listed;
variants with prevalence >99% within a patient’s viral population do not have the prevalence listed.
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; OBV, ombitasvir; PR, pegylated interferon plus ribavirin; PTV/RTV, ritonavir-
boosted paritaprevir; PTW, post-treatment week; TVR, telaprevir.
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patient prematurely discontinued treatment due to
adverse events. Clinical chemistry and hematology
revealed no signiﬁcant on-treatment abnormalities in
alanine aminotransferase (>3 3 upper limit of nor-
mal), aspartate aminotransferase (>3 3 upper limit of
normal), hemoglobin (<10 g/dL), or total bilirubin
(>33 upper limit of normal).
Discussion
The once-daily regimen of GLE and PIB was well
tolerated with no serious adverse events related to
study drug, no discontinuations due to adverse events,
and no relevant laboratory abnormalities. It also
resulted in high rates of SVR with or without coad-
ministration of RBV in patients with HCV GT1
infection and prior DAA therapy experience.
Overall, the DAA-experienced population in the
MAGELLAN-1 study had broad representation of
baseline NS3 and NS5A polymorphisms, including
polymorphisms at key NS5A positions M28, Q30,
L31, H58, and Y93 that confer resistance to earlier-
generation NS5A inhibitors. Additionally, all 8 patients
previously treated with ledipasvir/sofosbuvir achieved
SVR12 despite the presence of the NS5A resistance-
associated Y93H/N polymorphism in 5 patients and
multiple NS5A polymorphisms in 4 patients. This
conﬁrms in vitro data that variants at the Y93 position
are susceptible to PIB(22) and suggests GLE plus PIB
is an effective treatment for those with a baseline poly-
morphism or treatment-emergent substitution at this
position. Furthermore, 14 of 15 (93%) patients who
failed a prior dual (NS3/4A PI plus NS5A inhibitor)
or triple (NS3/4A PI plus NS5A inhibitor plus NS5B
polymerase inhibitor) DAA regimen achieved SVR12.
The addition of RBV to the GLE 1 PIB regimen
had no apparent impact on response as the rates of
virologic failure were identical in arms B and arm C by
mITT analysis. All 5 patients who modiﬁed RBV dose
achieved SVR12, similar to ﬁndings with other DAA
regimens.(25-27) However, this study did not have a
large enough sample size for sufﬁcient statistical power
to conﬁrm the impact of RBV on SVR. The patient
with virologic relapse in the RBV-containing arm had
prior treatment with two different therapeutic regi-
mens: daclatasvir alone and telaprevir plus pegylated
interferon with RBV. This patient had L31M and
H58D in NS5A at baseline; at the time of virologic
failure at posttreatment week 4, a Q30R substitution
emerged in this patient in addition to L31M and
H58D from baseline. The 1 other patient in this study
with a baseline H58D mutation in NS5A also had
baseline M28V and Q30R polymorphisms (instead of
L31M) in the same target, with an additional Q80K
polymorphism in NS3; and this patient achieved
SVR12. The patient with virologic breakthrough was
on immunosuppressive therapy for Crohn’s disease and
had prior ileocolectomy; it is unclear whether this con-
tributed to virologic failure. This patient had three
NS5A baseline polymorphisms (M28V, Q30R, and
H58C) and NS3 baseline polymorphisms at amino
acid positions Y56 and D168 that were maintained
until virologic failure. While 3 other patients with
baseline D168 polymorphisms achieved SVR12, this
was the only patient with a baseline Y56 polymor-
phism. The NS3 V36M and NS5A M28G substitu-
tions emerged in this patient after virologic failure.
TABLE 3. Adverse Events
Event, n (%)
GLE 1 PIB
(200 mg 1 80 mg)
n 5 6
GLE 1 PIB
(300 mg 1 80 mg) 1
RBV (800 mg) n 5 22
GLE 1 PIB
(300 mg 1 120 mg)
n 5 22
Adverse events
Any 5 (83.3) 19 (86.4) 18 (81.8)
Serious 1 (16.7)* 1 (4.5)† 0
Discontinuation as a result 0 0 0
Common adverse events‡
Headache 1 (16.7) 5 (22.7) 8 (36.4)
Fatigue 1 (16.7) 8 (36.4) 4 (18.2)
Nausea 1 (16.7) 6 (27.3) 3 (13.6)
Insomnia 0 6 (27.3) 0
Serious adverse events were deﬁned as events resulting in hospitalization or prolongation of hospitalization, persistent or clinically sig-
niﬁcant disability or incapacity, or death or that were life-threatening or required medical or surgical intervention to prevent a serious
outcome.
*Breast cancer.
†Fractured femur.
‡Occurring in >10% of all patients.
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Both patients who had virologic failure were reported
as compliant and had drug exposures similar to other
patients.
No clinically signiﬁcant laboratory abnormalities
were reported in hemoglobin levels, including in the
RBV-containing arm. Furthermore, no clinically sig-
niﬁcant chemistry values were observed, including on-
treatment elevations in total bilirubin or alanine ami-
notransferase >3 times the upper limit of normal after
alanine aminotransferase normalization or nadir.
Although no serious adverse events related to study
drug were reported in either arm, the addition of RBV
did not reduce the rate of virologic failure but did
increase the rate of adverse events. One potential limi-
tation of this study was that RBV coadministration
was 800 mg daily, regardless of patient weight, i.e.,
below the conventional 1,000 or 1,200 mg weight-
based RBV dosing. Because of this, it is unclear
whether weight-based RBV coadministration could
have increased the efﬁcacy in arm B. By corollary, it is
also likely that a conventional weight-based RBV dose
would have resulted in a further increased rate of
adverse events for these patients when compared to
that seen with the lower dose of RBV in arm B as
increasing side effects with higher RBV dose is well
documented.(28) However, regardless of comparison
between treatment arms, the low rate of virologic fail-
ure in the RBV-sparing arm suggests that the response
rate is already near maximal, and the addition of RBV
may not impact this. The patient population enrolled
here is considered inherently difﬁcult to cure, owing to
increased prevalence of baseline resistance-associated
polymorphisms likely stemming from prior DAA fail-
ure.(15,29-32) As such, additional study is required in
this diverse patient population to further conﬁrm efﬁ-
cacy of the regimen in GT1 patients with prior failure
of DAA therapy, including patients with prior expo-
sure to DAA-containing therapies and concomitant
cirrhosis, who were excluded here.
In summary, the combination of GLE and PIB
showed potent antiviral activity, regardless of the pres-
ence of one or more baseline resistance-associated
polymorphisms and irrespective of previous DAA-
containing treatment regimens, resulting in high
SVR12 rates in patients without cirrhosis but with
HCV GT1 infection. This suggests that the combina-
tion of GLE and PIB is highly effective in this popula-
tion, which currently has limited treatment options.
Based on these ﬁndings, larger and more diverse
patient groups are being evaluated in phase 3 studies to
conﬁrm the safety and efﬁcacy of the RBV-free
coformulation of GLE/PIB (300 mg/120 mg) in all six
major HCV GTs, including patients with prior DAA
experience and compensated cirrhosis.
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